• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • News
  • FAQs
    1. Home
    2. Stocks
    3. Lupin Share Price

    Lupin Share PriceLupin

    Large Cap 4.2k Result
    ₹821.65
    1.35 (0.16%)
    • Advice
    • Hold
    As on 07 June, 2023 | 04:06 BSE: 500257 NSE: LUPIN
    Announcements Dividends

    Lupin Performance

    Day Range

    • Low
    • High
    821.65

    52 Week Range

    • Low
    • High
    821.65
    • Open Price
    • Previous Close
    • Volume

    Start SIP in Lupin

    Start SIP

    Lupin Share Price

    • Over 1 Month 16.65%
    • Over 3 Month 24.03%
    • Over 6 Month 7.03%
    • Over 1 Year 35.71%

    Lupin Key Statistics

    P/E Ratio 86.9
    PEG Ratio 0.7
    Market Cap Cr 37,390
    Price to Book Ratio 3
    EPS 9.3
    Dividend 0.5
    Relative Strength Index 80.85
    Money Flow Index 74.8
    MACD Signal 25.17
    Average True Range 15.78

    Lupin F&O

    Lupin Futures
    Lupin Options

    Lupin Investment Rating

    • Master Rating:

    • Lupin (Nse) has an operating revenue of Rs. 16,641.66 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 4% needs improvement, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 15% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 73 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 93 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Lupin Financials
    IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2,7452,8612,8292,6842,504
    Operating Expenses Qtr Cr 2,5742,6462,5152,4442,354
    Operating Profit Qtr Cr 262215314289501
    Depreciation Qtr Cr 146134138130131
    Interest Qtr Cr 2931182025
    Tax Qtr Cr 23272428397
    Net Profit Qtr Cr 11940149117-36

    Lupin Technicals

    EMA & SMA

    Current Price
    ₹821.65
    1.35 (0.16%)
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹785.14
    • 50 Day
    • ₹746.73
    • 100 Day
    • ₹726.63
    • 200 Day
    • ₹723.92
    • 20 Day
    • ₹788.74
    • 50 Day
    • ₹724.56
    • 100 Day
    • ₹714.79
    • 200 Day
    • ₹710.89

    Lupin Resistance and Support

    PIVOT
    ₹823.22
    Resistance
    First Resistance ₹828.44
    Second Resistance ₹836.57
    Third Resistance ₹841.79
    RSI 80.85
    MFI 74.8
    MACD Single Line 25.17
    MACD 26
    Support
    First Resistance ₹815.09
    Second Resistance ₹809.87
    Third Resistance ₹801.74

    Lupin Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 454,600 15,892,816 34.96
    Week 947,374 35,810,730 37.8
    1 Month 1,201,178 32,948,309 27.43
    6 Month 1,004,955 30,148,636 30

    Lupin Result Highlights

    Lupin Synopsis

    NSE-Medical-Generic Drugs

    Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11258.83 Cr. and Equity Capital is Rs. 91.00 Cr. for the Year ended 31/03/2023. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
    Market Cap 37,390
    Sales 11,259
    Shares in Float 24.12
    No of funds 561
    Yield 0.49
    Book Value 2.03
    U/D Vol ratio 2.9
    LTDebt / Equity
    Alpha 0.1
    Beta 0.68

    Lupin

    Owner NameMar-23Dec-22Sep-22Jun-22
    Promoters 47.08%47.1%47.11%47.1%
    Mutual Funds 16.96%16.47%16.44%15.86%
    Insurance Companies 11.73%11.39%10.96%10.82%
    Foreign Portfolio Investors 13.32%13.98%13.81%14.27%
    Financial Institutions/ Banks 0.14%0.14%0.14%0.14%
    Individual Investors 7.86%8.06%8.41%8.59%
    Others 2.91%2.86%3.13%3.22%

    Lupin Management

    Name Designation
    Mrs. Manju D Gupta Chairman
    Dr. Kamal K Sharma Vice Chairman
    Mr. Nilesh D Gupta Managing Director
    Ms. Vinita Gupta Executive Director & CEO
    Mr. Ramesh Swaminathan Executive Director & Global CFO
    Mr. Jean-Luc Belingard Independent Director
    Ms. Christine Mundkur Independent Director
    Mr. K B S Anand Independent Director
    Dr. Punita Kumar-Sinha Independent Director
    Mr. Mark D McDade Independent Director

    Lupin Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Lupin Corporate Action

    Date Purpose Remarks
    2023-05-09 Audited Results & Final Dividend
    2023-02-09 Quarterly Results
    2022-11-09 Quarterly Results
    2022-08-03 Quarterly Results
    2022-05-18 Audited Results & Final Dividend
    Date Purpose Remarks
    2022-07-15 FINAL Rs.4.00 per share(200%)Final Dividend
    2021-07-28 FINAL Rs.6.50 per share(325%)Final Dividend

    Lupin MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 54413
    ICICI Prudential Balanced Advantage Fund Growth 45584
    ICICI Prudential Bluechip Fund Growth 35877
    HDFC Flexi Cap Fund Growth 33222
    ICICI Prudential Value Discovery Fund Growth 28471

    About Company

    Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices. 

    Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
     
    Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio. 

    Business Verticals

    1. Global Formulations
    2. Active Pharmaceuticals Ingredients (API)
    3. Biotech
    4. Specialty Business
    5. Over The Counter (OTC)
    6. Biosimilars
    7. Generic drugs


    Company History

    Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.

    Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs. 
     

    Milestones
     

    1968 - Dr Desh Bandhu Gupta started Lupin.

    1972 - Lupin Laboratories Pvt. Ltd. was incorporated.

    1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.

    1981 - They started the production of Ethambutol.

    1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.

    1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).

    1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.

    1991 - Initiated the production of injectable Cephalosporin at Mandideep.

    1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.

    1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.

    1997 - Three facilities received U.S. FDA approvals.

    2000 - Another plant received US FDA approval.

    2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.

    2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.

    2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.

    2004 - Started U.S. brands’ business with the launch of Suprax.

    2005 - Commenced its generics business in the U.S. Implemented ESOP.

    2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.

    2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.

    2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.

    2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.

    2010 - Lupin ranked the 5th largest generic player in the U.S.

    2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.

    2012 - Lupin enters Nifty 50.

    2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.

    2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.

    2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.

    2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.

    2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd., in Osaka.

    2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.

    Lupin FAQs

    What is Share Price of Lupin ?

    Lupin share price is ₹821 As on 07 June, 2023 | 03:52

    What is the Market Cap of Lupin ?

    The Market Cap of Lupin is ₹37390.2 Cr As on 07 June, 2023 | 03:52

    What is the P/E ratio of Lupin ?

    The P/E ratio of Lupin is 86.9 As on 07 June, 2023 | 03:52

    What is the PB ratio of Lupin ?

    The PB ratio of Lupin is 3 As on 07 June, 2023 | 03:52

    What were the company's reported sales and net income in 2022?

    For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.

    What is the future of Lupin Limited's shares?

    Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.

    How to buy Lupin’s shares?

    You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.
     

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Enter Mobile Number

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from NSDL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.

    Start Investing Now!

    Open Free Demat Account in 5 mins

    Enter Valid Mobile Number